Get Premium to unlock powerful stock data

Silverarc Capital Management, Llc Buys Galapagos NV, Immunogen Inc, Apollo Endosurgery Inc, Sells Fulcrum Therapeutics Inc, NextCure Inc, Arvinas Inc

Author's Avatar
Feb 15, 2022
Article's Main Image
Investment company Silverarc Capital Management, Llc (Current Portfolio) buys Galapagos NV, Immunogen Inc, Apollo Endosurgery Inc, BELLUS Health Inc, Intra-Cellular Therapies Inc, sells Fulcrum Therapeutics Inc, NextCure Inc, Arvinas Inc, Insmed Inc, Amryt Pharma PLC during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Silverarc Capital Management, Llc. As of 2021Q4, Silverarc Capital Management, Llc owns 71 stocks with a total value of $247 million. These are the details of the buys and sells.

For the details of SILVERARC CAPITAL MANAGEMENT, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/silverarc+capital+management%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of SILVERARC CAPITAL MANAGEMENT, LLC
  1. SPDR Biotech ETF (XBI) - 200,000 shares, 9.07% of the total portfolio.
  2. Immunogen Inc (IMGN) - 1,514,411 shares, 4.55% of the total portfolio. Shares added by 133.02%
  3. Biohaven Pharmaceutical Holding Co Ltd (BHVN) - 80,348 shares, 4.49% of the total portfolio. Shares added by 29.81%
  4. Intra-Cellular Therapies Inc (ITCI) - 195,000 shares, 4.14% of the total portfolio. Shares added by 91.38%
  5. Merus NV (MRUS) - 320,174 shares, 4.13% of the total portfolio. Shares reduced by 7.45%
New Purchase: Galapagos NV (GLPG)

Silverarc Capital Management, Llc initiated holding in Galapagos NV. The purchase prices were between $47.03 and $57.12, with an estimated average price of $52.17. The stock is now traded at around $66.450000. The impact to a portfolio due to this purchase was 2.88%. The holding were 128,901 shares as of 2021-12-31.

New Purchase: Apollo Endosurgery Inc (APEN)

Silverarc Capital Management, Llc initiated holding in Apollo Endosurgery Inc. The purchase prices were between $7.64 and $10.11, with an estimated average price of $8.72. The stock is now traded at around $5.575000. The impact to a portfolio due to this purchase was 2.53%. The holding were 739,604 shares as of 2021-12-31.

New Purchase: CTI BioPharma Corp (CTIC)

Silverarc Capital Management, Llc initiated holding in CTI BioPharma Corp. The purchase prices were between $1.44 and $2.82, with an estimated average price of $2.44. The stock is now traded at around $2.320000. The impact to a portfolio due to this purchase was 1.49%. The holding were 1,483,829 shares as of 2021-12-31.

New Purchase: Krystal Biotech Inc (KRYS)

Silverarc Capital Management, Llc initiated holding in Krystal Biotech Inc. The purchase prices were between $39.81 and $88.24, with an estimated average price of $58.25. The stock is now traded at around $66.780000. The impact to a portfolio due to this purchase was 1.32%. The holding were 46,670 shares as of 2021-12-31.

New Purchase: Aurinia Pharmaceuticals Inc (AUPH)

Silverarc Capital Management, Llc initiated holding in Aurinia Pharmaceuticals Inc. The purchase prices were between $17.78 and $33.08, with an estimated average price of $23.65. The stock is now traded at around $18.450000. The impact to a portfolio due to this purchase was 0.93%. The holding were 100,000 shares as of 2021-12-31.

New Purchase: Syndax Pharmaceuticals Inc (SNDX)

Silverarc Capital Management, Llc initiated holding in Syndax Pharmaceuticals Inc. The purchase prices were between $15.23 and $22.47, with an estimated average price of $18.5. The stock is now traded at around $16.450000. The impact to a portfolio due to this purchase was 0.89%. The holding were 100,000 shares as of 2021-12-31.

Added: Immunogen Inc (IMGN)

Silverarc Capital Management, Llc added to a holding in Immunogen Inc by 133.02%. The purchase prices were between $4.75 and $7.5, with an estimated average price of $6.22. The stock is now traded at around $5.730000. The impact to a portfolio due to this purchase was 2.6%. The holding were 1,514,411 shares as of 2021-12-31.

Added: BELLUS Health Inc (BLU)

Silverarc Capital Management, Llc added to a holding in BELLUS Health Inc by 201.37%. The purchase prices were between $5.26 and $8.3, with an estimated average price of $6.65. The stock is now traded at around $7.155000. The impact to a portfolio due to this purchase was 2.4%. The holding were 1,100,000 shares as of 2021-12-31.

Added: Intra-Cellular Therapies Inc (ITCI)

Silverarc Capital Management, Llc added to a holding in Intra-Cellular Therapies Inc by 91.38%. The purchase prices were between $35.2 and $53.42, with an estimated average price of $42.23. The stock is now traded at around $55.660000. The impact to a portfolio due to this purchase was 1.98%. The holding were 195,000 shares as of 2021-12-31.

Added: Cerus Corp (CERS)

Silverarc Capital Management, Llc added to a holding in Cerus Corp by 68.35%. The purchase prices were between $5.97 and $7.93, with an estimated average price of $6.75. The stock is now traded at around $5.480000. The impact to a portfolio due to this purchase was 1.17%. The holding were 1,042,722 shares as of 2021-12-31.

Added: Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Silverarc Capital Management, Llc added to a holding in Biohaven Pharmaceutical Holding Co Ltd by 29.81%. The purchase prices were between $99.73 and $148.48, with an estimated average price of $126.83. The stock is now traded at around $141.220000. The impact to a portfolio due to this purchase was 1.03%. The holding were 80,348 shares as of 2021-12-31.

Added: Lucira Health Inc (LHDX)

Silverarc Capital Management, Llc added to a holding in Lucira Health Inc by 133.29%. The purchase prices were between $4.94 and $8.94, with an estimated average price of $6.38. The stock is now traded at around $4.665000. The impact to a portfolio due to this purchase was 1.03%. The holding were 515,000 shares as of 2021-12-31.

Sold Out: Fulcrum Therapeutics Inc (FULC)

Silverarc Capital Management, Llc sold out a holding in Fulcrum Therapeutics Inc. The sale prices were between $14 and $28.44, with an estimated average price of $19.58.

Sold Out: Arvinas Inc (ARVN)

Silverarc Capital Management, Llc sold out a holding in Arvinas Inc. The sale prices were between $65.85 and $96.21, with an estimated average price of $81.26.

Sold Out: Erasca Inc (ERAS)

Silverarc Capital Management, Llc sold out a holding in Erasca Inc. The sale prices were between $12.51 and $22.75, with an estimated average price of $17.

Sold Out: Zentalis Pharmaceuticals Inc (ZNTL)

Silverarc Capital Management, Llc sold out a holding in Zentalis Pharmaceuticals Inc. The sale prices were between $66.92 and $84.79, with an estimated average price of $77.64.

Sold Out: (ADMS)

Silverarc Capital Management, Llc sold out a holding in . The sale prices were between $4.51 and $8.23, with an estimated average price of $7.66.

Sold Out: Arena Pharmaceuticals Inc (ARNA)

Silverarc Capital Management, Llc sold out a holding in Arena Pharmaceuticals Inc. The sale prices were between $49.55 and $92.95, with an estimated average price of $66.26.



Here is the complete portfolio of SILVERARC CAPITAL MANAGEMENT, LLC. Also check out:

1. SILVERARC CAPITAL MANAGEMENT, LLC's Undervalued Stocks
2. SILVERARC CAPITAL MANAGEMENT, LLC's Top Growth Companies, and
3. SILVERARC CAPITAL MANAGEMENT, LLC's High Yield stocks
4. Stocks that SILVERARC CAPITAL MANAGEMENT, LLC keeps buying
Rating:
0 / 5 (0 votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus